Alexander Kleinman
Publications
ABC-Bench: An Agentic Bio-Capabilities Benchmark for Biosecurity
Large language models (LLMs) are rapidly acquiring capabilities relevant to biological research, from literature synthesis to interpretation of experimental data. Increasingly, LLM agents can also perform in silico biology tasks that previously required experienced human biologists. These emerging AI capabilities offer new opportunities for scientific discovery and biomedical advances, but they also shift the landscape of biosecurity risks. To address this, we introduce the Agentic Bio-Capabilities Benchmark (ABC-Bench), a suite of tasks to measure agentic biosecurity-relevant capabilities. ABC-Bench evaluates LLM agents on both benign and dual-use biology tasks: writing code to operate liquid handling robots, designing DNA fragments for in vitro assembly, and evading DNA synthesis screening. These tasks require a combination of biology and software expertise. All tested LLM agents outperformed the median expert human baseliner on all three tasks. Agents performed highly on tasks drawing on published knowledge and well-documented protocols, and more weakly on a task requiring novel bioinformatics reasoning. In three wet-lab validation experiments, we found that OpenAI's o4-mini-high produced scripts that, when run on an OpenTrons liquid handling robot, successfully assembled DNA with expected sequences.
Measuring Mid-2025 LLM-Assistance on Novice Performance in Biology
Large language models (LLMs) perform strongly on biological benchmarks, raising concerns that they may help novice actors acquire dual-use laboratory skills. Yet, whether this translates to improved human performance in the physical laboratory remains unclear. To address this, we conducted a pre-registered, investigator-blinded, randomized controlled trial (June-August 2025; n = 153) evaluating whether LLMs improve novice performance in tasks that collectively model a viral reverse genetics workflow. We observed no significant difference in the primary endpoint of workflow completion (5.2% LLM vs. 6.6% Internet; P = 0.759), nor in the success rate of individual tasks. However, the LLM arm had numerically higher success rates in four of the five tasks, most notably for the cell culture task (68.8% LLM vs. 55.3% Internet; P = 0.059). Post-hoc Bayesian modeling of pooled data estimates an approximate 1.4-fold increase (95% CrI 0.74-2.62) in success for a "typical" reverse genetics task under LLM assistance. Ordinal regression modelling suggests that participants in the LLM arm were more likely to progress through intermediate steps across all tasks (posterior probability of a positive effect: 81%-96%). Overall, mid-2025 LLMs did not substantially increase novice completion of complex laboratory procedures but were associated with a modest performance benefit. These results reveal a gap between in silico benchmarks and real-world utility, underscoring the need for physical-world validation of AI biosecurity assessments as model capabilities and user proficiency evolve.